vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $170.6M, roughly 1.2× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 57.4%, a 19.8% gap on every dollar of revenue. Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $142.2M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
IDYA vs PTGX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $170.6M |
| Net Profit | $119.2M | $131.7M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | 74.3% |
| Net Margin | 57.4% | 77.2% |
| Revenue YoY | — | 184.4% |
| Net Profit YoY | 330.1% | 381.7% |
| EPS (diluted) | $1.33 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $207.8M | — | ||
| Q4 24 | — | $170.6M | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | $255.0M | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 | ||
| Q1 23 | — | $0 |
| Q3 25 | $119.2M | — | ||
| Q4 24 | — | $131.7M | ||
| Q3 24 | $-51.8M | — | ||
| Q2 24 | $-52.8M | — | ||
| Q1 24 | $-39.6M | $207.3M | ||
| Q3 23 | — | $-34.1M | ||
| Q2 23 | — | $-38.5M | ||
| Q1 23 | — | $-33.7M |
| Q3 25 | 52.2% | — | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 80.9% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | 57.4% | — | ||
| Q4 24 | — | 77.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 81.3% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | $1.33 | — | ||
| Q4 24 | — | $2.01 | ||
| Q3 24 | $-0.60 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | $3.26 | ||
| Q3 23 | — | $-0.58 | ||
| Q2 23 | — | $-0.68 | ||
| Q1 23 | — | $-0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $418.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $675.3M |
| Total Assets | $1.2B | $744.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $786.9M | — | ||
| Q4 24 | — | $418.9M | ||
| Q3 24 | $920.0M | — | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | $322.6M | ||
| Q3 23 | — | $320.8M | ||
| Q2 23 | — | $313.4M | ||
| Q1 23 | — | $230.8M |
| Q3 25 | $1.1B | — | ||
| Q4 24 | — | $675.3M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $935.3M | $560.4M | ||
| Q3 23 | — | $302.1M | ||
| Q2 23 | — | $294.1M | ||
| Q1 23 | — | $216.2M |
| Q3 25 | $1.2B | — | ||
| Q4 24 | — | $744.7M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $973.7M | — | ||
| Q1 24 | $961.5M | $629.3M | ||
| Q3 23 | — | $330.0M | ||
| Q2 23 | — | $320.5M | ||
| Q1 23 | — | $239.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $184.2M |
| Free Cash FlowOCF − Capex | $142.2M | $182.8M |
| FCF MarginFCF / Revenue | 68.4% | 107.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.19× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.2M | — | ||
| Q4 24 | — | $184.2M | ||
| Q3 24 | $-49.2M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-43.8M | $-27.4M | ||
| Q3 23 | — | $-26.6M | ||
| Q2 23 | — | $-26.2M | ||
| Q1 23 | — | $-34.3M |
| Q3 25 | $142.2M | — | ||
| Q4 24 | — | $182.8M | ||
| Q3 24 | $-49.7M | — | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | $-27.7M | ||
| Q3 23 | — | $-27.0M | ||
| Q2 23 | — | $-26.4M | ||
| Q1 23 | — | $-34.4M |
| Q3 25 | 68.4% | — | ||
| Q4 24 | — | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -10.9% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | 0.0% | — | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.1% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | 1.19× | — | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.13× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
